Friday, the Food and Drug Administration approved the very first home test for the screening of the cervical cancer, developed by Startup Health, based in San Francisco.
The company began to develop the prototype of its turaille wand just over five years ago. The concept was to make the cervical cancer screening more accessible via the remote chart and a test that could be self-administered at home, rather than in a doctor's office.
“The pandemic has shown everyone that Télésanté is something that is preferred … and has facilitated the management of most Americans,” said Kara Egan, CEO of Teal Health, adding that Covid has also demonstrated “home tests were something that people could manage and really understand”.
The Sarcelle wand works a bit like a buffer applicator, with a large swab that the user can fit to collect a sample for tests. The FDA has appointed the tool as a revolutionary device after the results of the clinical trial of the company showed that the accuracy of the self-administered test was comparable to an office screening carried out by a clinician, with a 96%precision rate.
Teal plans to make the wand available in California first, from June.
The company had discussions with carriers on insurance coverage for the test as a preventive screening, which for most women would be covered without Copays as well as an annual visit to the doctor.
The American Cancer Society recommends women to be detected for cervical cancer every three years from the age of 21.
However, Egan says that 1 out of 4 women are late on screening, in part because they do not find time for a gynecologist in person, a particular problem for women in rural areas which often have to travel beyond their community to go to a doctor.
“It is a question of increasing access to care and making sure that we have more options to get this care,” she said.
Before its expected FDA approval, Teal Health collected $ 10 million during its last financing round in January to help accelerate production for the launch of the turacal wand. The investment was led by Forerunner Ventures and Collective Emerson by Laurene Powell Jobs. The company has raised a total of $ 23 million from investors, including Serena Williams, Serena Ventures, as well as the Labcorp test company.
The milestone of the company intervenes while investors were more interested in women's health technologies.
Last year, there was an influx of $ 680 million in the space invested in 30 transactions, according to Deloitte data. According to Jen Radin, director of investments in a subsequent stage, around 60% of these funds, the main life sciences of Deloitte and the practice of health care.
“From 2023 to 2024, Femtech experienced growth of 41%, exceeding global health technology, which has only increased by 10%,” said Radin.
The general partner of Femhealth Ventures, Maneesha Ghiya, says that if investors are now more prudent, in general, the interest in women's health technology goes beyond maternity and menopause.
“Many more people think more about women's health and support these types of innovations – and that includes major established players like Medtech, Pharma, Biotech, large public companies that think more about women's health,” said Ghiya.